Phenotypic screening in cancer drug discovery — past, present and future (original) (raw)

• Swinney, D. C. Phenotypic versus target-based drug discovery for first-in-class medicines. Clin. Pharmacol. Ther. 93, 299–301 (2013).
  CAS PubMed Google Scholar
• Sams-Dodd, F. Is poor research the cause of the declining productivity of the pharmaceutical industry? An industry in need of a paradigm shift. Drug Discov. Today 18, 211–217 (2013).
  PubMed Google Scholar
• Sams-Dodd, F. Target-based drug discovery: is something wrong? Drug Discov. Today 10, 139–147 (2005).
  CAS PubMed Google Scholar
• Hopkins, A. L. Network pharmacology: the next paradigm in drug discovery. Nature Chem. Biol. 4, 682–690 (2008).
  CAS Google Scholar
• Overington, J. P., Al-Lazikani, B. & Hopkins, A. L. How many drug targets are there? Nature Rev. Drug Discov. 5, 993–996 (2006).
  CAS Google Scholar
• Butcher, E. C. Can cell systems biology rescue drug discovery? Nature Rev. Drug Discov. 4, 461–467 (2005).
  CAS Google Scholar
• Paul, S. M. et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nature Rev. Drug Discov. 9, 203–214 (2010).
  CAS Google Scholar
• Scannell, J. W., Blanckley, A., Boldon, H. & Warrington, B. Diagnosing the decline in pharmaceutical R&D efficiency. Nature Rev. Drug Discov. 11, 191–200 (2012).
  Article CAS Google Scholar
• Bennani, Y. L. Drug discovery in the next decade: innovation needed ASAP. Drug Discov. Today 16, 779–792 (2011).
  PubMed Google Scholar
• Hoelder, S., Clarke, P. A. & Workman, P. Discovery of small molecule cancer drugs: successes, challenges and opportunities. Mol. Oncol. 6, 155–176 (2012).
  CAS PubMed PubMed Central Google Scholar
• Lee, J. A., Uhlik, M. T., Moxham, C. M., Tomandl, D. & Sall, D. J. Modern phenotypic drug discovery is a viable, neoclassic pharma strategy. J. Med. Chem. 55, 4527–4538 (2012).
  CAS PubMed Google Scholar
• Swinney, D. C. & Anthony, J. How were new medicines discovered? Nature Rev. Drug Discov. 10, 507–519 (2011).
  Article CAS Google Scholar
• Arrowsmith, J. A decade of change. Nature Rev. Drug Discov. 11, 17–18 (2012).
  CAS Google Scholar
• Zhang, J., Yang, P. L. & Gray, N. S. Targeting cancer with small molecule kinase inhibitors. Nature Rev. Cancer 9, 28–39 (2009).
  Google Scholar
• Garraway, L. A. & Lander, E. S. Lessons from the cancer genome. Cell 153, 17–37 (2013).
  CAS PubMed Google Scholar
• Capdeville, R., Buchdunger, E., Zimmermann, J. & Matter, A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nature Rev. Drug Discov. 1, 493–502 (2002).
  CAS Google Scholar
• Williams, R. Discontinued drugs in 2012: oncology drugs. Expert Opin. Investig. Drugs 22, 1627–1644 (2013).
  CAS PubMed Google Scholar
• Ellis, L. M. & Fidler, I. J. Finding the tumor copycat. Therapy fails, patients don't. Nature Med. 16, 974–975 (2010).
  CAS PubMed Google Scholar
• Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57–70 (2000).
  CAS PubMed Google Scholar
• Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).
  CAS PubMed Google Scholar
• Carter, S. K. The search for therapeutic cell controls by the chemotherapy program of the National Cancer Institute. J. Invest. Dermatol. 59, 128–138 (1972).
  CAS PubMed Google Scholar
• DeVita, V. T. & Chu, E. A history of cancer chemotherapy. Cancer Res. 68, 8643–8653 (2008).
  CAS PubMed Google Scholar
• Kim, M.-J. et al. OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells. Cancer Lett. 335, 145–152 (2013).
  CAS PubMed Google Scholar
• Chan, D. A. & Giaccia, A. J. Harnessing synthetic lethal interactions in anticancer drug discovery. Nature Rev. Drug Discov. 10, 351–364 (2011).
  CAS Google Scholar
• Dolma, S., Lessnick, S. L., Hahn, W. C. & Stockwell, B. R. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell 3, 285–296 (2003).
  CAS PubMed Google Scholar
• Shaw, A. T. et al. Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress. Proc. Natl Acad. Sci. USA 108, 8773–8778 (2011).
  CAS PubMed PubMed Central Google Scholar
• Weïwer, M. et al. Development of small-molecule probes that selectively kill cells induced to express mutant RAS. Bioorg. Med. Chem. Lett. 22, 1822–1826 (2012).
  PubMed Google Scholar
• Yoshida, T. et al. Identification and characterization of a novel chemotype MEK inhibitor able to alter the phosphorylation state of MEK1/2. Oncotarget 3, 1533–1545 (2012).
  PubMed PubMed Central Google Scholar
• Teicher, B. A., Ara, G., Herbst, R., Palombella, V. J. & Adams, J. The proteasome inhibitor PS-341 in cancer therapy. Clin. Cancer Res. 5, 2638–2645 (1999).
  CAS PubMed Google Scholar
• O'Donnell, A. et al. Hormonal impact of the 17α-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br. J. Cancer 90, 2317–2325 (2004).
  CAS PubMed PubMed Central Google Scholar
• Boehm, M. F. et al. Design and synthesis of potent retinoid X receptor selective ligands that induce apoptosis in leukemia cells. J. Med. Chem. 38, 3146–3155 (1995).
  CAS PubMed Google Scholar
• Marks, P. A. & Breslow, R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nature Biotech. 25, 84–90 (2007).
  CAS Google Scholar
• Shortt, J., Hsu, A. K. & Johnstone, R. W. Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy. Oncogene 32, 4191–4202 (2013).
  CAS PubMed Google Scholar
• Lopez-Girona, A. et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 26, 2326–2335 (2012).
  CAS PubMed PubMed Central Google Scholar
• Licht, J. D., Shortt, J. & Johnstone, R. From anecdote to targeted therapy: the curious case of thalidomide in multiple myeloma. Cancer Cell 25, 9–11 (2014).
  CAS PubMed PubMed Central Google Scholar
• Friend, C., Scher, W., Holland, J. G. & Sato, T. Hemoglobin synthesis in murine virus-induced leukemic cells in vitro: stimulation of erythroid differentiation by dimethyl sulfoxide. Proc. Natl Acad. Sci. USA 68, 378–382 (1971).
  CAS PubMed PubMed Central Google Scholar
• Ueda, H. et al. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. J. Antibiot. 47, 301–310 (1994).
  CAS Google Scholar
• Nakajima, H., Kim, Y. B., Terano, H., Yoshida, M. & Horinouchi, S. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp. Cell Res. 241, 126–133 (1998).
  CAS PubMed Google Scholar
• Hartford, C. M. & Ratain, M. J. Rapamycin: something old, something new, sometimes borrowed and now renewed. Clin. Pharmacol. Ther. 82, 381–388 (2007).
  CAS PubMed Google Scholar
• Kuhn, D. J. et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood 110, 3281–3290 (2007).
  CAS PubMed PubMed Central Google Scholar
• Huang, M. T. Harringtonine, an inhibitor of initiation of protein biosynthesis. Mol. Pharmacol. 11, 511–519 (1975).
  CAS PubMed Google Scholar
• Jordan, M. A. et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol. Cancer Ther. 4, 1086–1095 (2005).
  CAS PubMed Google Scholar
• Tran, C. et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324, 787–790 (2009).
  CAS PubMed PubMed Central Google Scholar
• Wakeling, A. E. & Bowler, J. I.C. I. 182,780, a new antioestrogen with clinical potential. J. Steroid Biochem. Mol. Biol. 43, 173–177 (1992).
  CAS PubMed Google Scholar
• Lee, F. Y. F. et al. Preclinical discovery of ixabepilone, a highly active antineoplastic agent. Cancer Chemother. Pharmacol. 63, 157–166 (2008).
  CAS PubMed Google Scholar
• Galsky, M. D., Dritselis, A., Kirkpatrick, P. & Oh, W. K. Cabazitaxel. Nature Rev. Drug Discov. 9, 677–678 (2010).
  CAS Google Scholar
• Gandhi, V., Keating, M. J., Bate, G. & Kirkpatrick, P. Nelarabine. Nature Rev. Drug Discov. 5, 17–18 (2006).
  CAS Google Scholar
• Adjei, A. A. Pemetrexed: a multitargeted antifolate agent with promising activity in solid tumors. Ann. Oncol. 11, 1335–1341 (2000).
  CAS PubMed Google Scholar
• Giuliani, F. C. & Kaplan, N. O. New doxorubicin analogs active against doxorubicin-resistant colon tumor xenografts in the nude mouse. Cancer Res. 40, 4682–4687 (1980).
  CAS PubMed Google Scholar
• Gould, S. E. et al. Discovery and preclinical development of vismodegib. Expert Opin. Drug Discov. http://dx.doi.org/10.1517/17460441.2014.920816 (2014).
• O'Dwyer, K. & Maslak, P. Azacitidine and the beginnings of therapeutic epigenetic modulation. Expert Opin. Pharmacother. 9, 1981–1986 (2008).
  CAS PubMed Google Scholar
• Iyer, R., Fetterly, G., Lugade, A. & Thanavala, Y. Sorafenib: a clinical and pharmacologic review. Expert Opin. Pharmacother. 11, 1943–1955 (2010).
  CAS PubMed Google Scholar
• Isaacs, J. T. The long and winding road for the development of tasquinimod as an oral second-generation quinoline-3-carboxamide antiangiogenic drug for the treatment of prostate cancer. Expert Opin. Investig. Drugs 19, 1235–1243 (2010).
  CAS PubMed PubMed Central Google Scholar
• Isaacs, J. T. et al. Tasquinimod is an allosteric modulator of HDAC4 survival signaling within the compromised cancer microenvironment. Cancer Res. 73, 1386–1399 (2013).
  CAS PubMed Google Scholar
• Yagoda, N. et al. RAS–RAF–MEK-dependent oxidative cell death involving voltage-dependent anion channels. Nature 447, 864–868 (2007).
  PubMed PubMed Central Google Scholar
• Wong, H. et al. Antitumor activity of targeted and cytotoxic agents in murine subcutaneous tumor models correlates with clinical response. Clin. Cancer Res. 18, 3846–3855 (2012).
  CAS PubMed Google Scholar
• Wong, H. et al. Bridging the gap between preclinical and clinical studies using pharmacokinetic-pharmacodynamic modeling: an analysis of GDC-0973, a MEK inhibitor. Clin. Cancer Res. 18, 3090–3099 (2012).
  CAS PubMed Google Scholar
• Prinz, F., Schlange, T. & Asadullah, K. Believe it or not: how much can we rely on published data on potential drug targets? Nature Rev. Drug Discov. 10, 712–712 (2011).
  CAS Google Scholar
• Begley, C. G. & Ellis, L. M. Drug development: raise standards for preclinical cancer research. Nature 483, 531–533 (2012).
  CAS PubMed Google Scholar
• Swinney, D. C. The contribution of mechanistic understanding to phenotypic screening for first-in-class medicines. J. Biomol. Screen. 18, 1186–1192 (2013).
  PubMed Google Scholar
• Mangana, J., Levesque, M. P., Karpova, M. B. & Dummer, R. Sorafenib in melanoma. Expert Opin. Investig. Drugs 21, 557–568 (2012).
  CAS PubMed Google Scholar
• Munshi, N. et al. ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol. Cancer Ther. 9, 1544–1553 (2010).
  CAS PubMed Google Scholar
• Michieli, P. & Di Nicolantonio, F. Targeted therapies: Tivantinib — a cytotoxic drug in MET inhibitor's clothes? Nature Rev. Clin. Oncol. 10, 372–374 (2013).
  CAS Google Scholar
• Basilico, C. et al. Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET. Clin. Cancer Res. 19, 2381–2392 (2013).
  CAS PubMed Google Scholar
• Katayama, R. et al. Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition. Cancer Res. 73, 3087–3096 (2013).
  CAS PubMed PubMed Central Google Scholar
• Reddy, M. V. R. et al. Discovery of a clinical stage multi-kinase inhibitor sodium (E)-2-{2-methoxy-5-[(2′,4“,6”-trimethoxystyrylsulfonyl)methyl]phenylamino}acetate (ON 01910. Na): synthesis, structure-activity relationship, and biological activity. J. Med. Chem. 54, 6254–6276 (2011).
  CAS PubMed PubMed Central Google Scholar
• Jimeno, A. et al. Phase I study of ON 01910. Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors. J. Clin. Oncol. 26, 5504–5510 (2008).
  CAS PubMed PubMed Central Google Scholar
• Roschewski, M., Farooqui, M., Aue, G., Wilhelm, F. & Wiestner, A. Phase I study of ON 01910. Na (Rigosertib), a multikinase PI3K inhibitor in relapsed/refractory B-cell malignancies. Leukemia 27, 1920–1923 (2013).
  CAS PubMed PubMed Central Google Scholar
• Prasad, A. et al. Styryl sulfonyl compounds inhibit translation of cyclin D1 in mantle cell lymphoma cells. Oncogene 28, 1518–1528 (2009).
  CAS PubMed Google Scholar
• Chapman, C. M. et al. ON 01910. Na is selectively cytotoxic for chronic lymphocytic leukemia cells through a dual mechanism of action involving PI3K/AKT inhibition and induction of oxidative stress. Clin. Cancer Res. 18, 1979–1991 (2012).
  CAS PubMed PubMed Central Google Scholar
• Nakahara, T. et al. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res. 67, 8014–8021 (2007).
  CAS PubMed Google Scholar
• Glaros, T. G. et al. The 'survivin suppressants' NSC 80467 and YM155 induce a DNA damage response. Cancer Chemother. Pharmacol. 70, 207–212 (2012).
  CAS PubMed Google Scholar
• Lewis, K. D. et al. A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma. Invest. New Drugs 29, 161–166 (2009).
  PubMed Google Scholar
• Kelly, R. J. et al. A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer. Ann. Oncol. 24, 2601–2606 (2013).
  CAS PubMed PubMed Central Google Scholar
• Giaccone, G. et al. Multicenter Phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer. J. Clin. Oncol. 27, 4481–4486 (2009).
  CAS PubMed Google Scholar
• Coumar, M. S., Tsai, F.-Y., Kanwar, J. R., Sarvagalla, S. & Cheung, C. H. A. Treat cancers by targeting survivin: just a dream or future reality? Cancer Treat. Rev. 39, 802–811 (2013).
  CAS PubMed Google Scholar
• Ledford, H. Drug candidates derailed in case of mistaken identity. Nature 483, 519 (2012).
  CAS PubMed Google Scholar
• Hwang, S. G. et al. Anti-cancer activity of a novel small molecule compound that simultaneously activates p53 and inhibits NF-κB signaling. PLoS ONE 7, e44259 (2012).
  CAS PubMed PubMed Central Google Scholar
• Caie, P. D. et al. High-content phenotypic profiling of drug response signatures across distinct cancer cells. Mol. Cancer Ther. 9, 1913–1926 (2010).
  CAS PubMed Google Scholar
• Low, J. et al. Phenotypic fingerprinting of small molecule cell cycle kinase inhibitors for drug discovery. Curr. Chem. Genom. 3, 13–21 (2009).
  CAS Google Scholar
• Chan, G. K. Y., Kleinheinz, T. L., Peterson, D. & Moffat, J. G. A simple high-content cell cycle assay reveals frequent discrepancies between cell number and ATP and MTS proliferation assays. PLoS ONE 8, e63583 (2013).
  CAS PubMed PubMed Central Google Scholar
• Kimlin, L. C., Casagrande, G. & Virador, V. M. In vitro three-dimensional (3D) models in cancer research: an update. Mol. Carcinog. 52, 167–182 (2013).
  PubMed Google Scholar
• Harrison, R. G. The outgrowth of the nerve fiber as a mode of protoplasmic movement. J. Exp. Zool. 9, 787–846 (1910).
  Google Scholar
• Drewitz, M. et al. Towards automated production and drug sensitivity testing using scaffold-free spherical tumor microtissues. Biotechnol. J. 6, 1488–1496 (2011).
  CAS PubMed Google Scholar
• Hsiao, A. Y. et al. Micro-ring structures stabilize microdroplets to enable long term spheroid culture in 384 hanging drop array plates. Biomed. Microdevices 14, 313–323 (2012).
  CAS PubMed PubMed Central Google Scholar
• LaBarbera, D. V., Reid, B. G. & Yoo, B. H. The multicellular tumor spheroid model for high-throughput cancer drug discovery. Expert Opin. Drug Discov. 7, 819–830 (2012).
  CAS PubMed Google Scholar
• Li, Q. et al. 3D models of epithelial-mesenchymal transition in breast cancer metastasis: high-throughput screening assay development, validation, and pilot screen. J. Biomol. Screen. 16, 141–154 (2011).
  CAS PubMed Google Scholar
• Korff, T. Integration of endothelial cells in multicellular spheroids prevents apoptosis and induces differentiation. J. Cell Biol. 143, 1341–1352 (1998).
  CAS PubMed PubMed Central Google Scholar
• Friedrich, J., Seidel, C., Ebner, R. & Kunz-Schughart, L. A spheroid-based drug screen: considerations and practical approach. Nature Protoc. 4, 309–324 (2009).
  CAS Google Scholar
• Misund, K. et al. A method for measurement of drug sensitivity of myeloma cells co-cultured with bone marrow stromal cells. J. Biomol. Screen 18, 637–646 (2013).
  PubMed Google Scholar
• Haglund, C. et al. In vitro evaluation of clinical activity and toxicity of anticancer drugs using tumor cells from patients and cells representing normal tissues. Cancer Chemother. Pharmacol. 69, 697–707 (2012).
  CAS PubMed Google Scholar
• Carmody, L. C. et al. Phenotypic high-throughput screening elucidates target pathway in breast cancer stem cell-like cells. J. Biomol. Screen 17, 1204–1210 (2012).
  PubMed Google Scholar
• Valent, P. et al. Cancer stem cell definitions and terminology: the devil is in the details. Nature Rev. Cancer 12, 767–775 (2012).
  CAS Google Scholar
• Visvader, J. E. & Lindeman, G. J. Cancer stem cells: current status and evolving complexities. Cell Stem Cell 10, 717–728 (2012).
  CAS PubMed Google Scholar
• Romaguera-Ros, M. et al. Cancer-initiating enriched cell lines from human glioblastoma: preparing for drug discovery assays. Stem Cell Rev. 8, 288–298 (2012).
  CAS Google Scholar
• Lee, T. K. W., Cheung, V. C. H. & Ng, I. O. L. Liver tumor-initiating cells as a therapeutic target for hepatocellular carcinoma. Cancer Lett. 338, 101–109 (2013).
  CAS PubMed Google Scholar
• Izrailit, J. & Reedijk, M. Developmental pathways in breast cancer and breast tumor-initiating cells: therapeutic implications. Cancer Lett. 317, 115–126 (2012).
  CAS PubMed Google Scholar
• Morrison, B. J., Morris, J. C. & Steel, J. C. Lung cancer-initiating cells: a novel target for cancer therapy. Target Oncol. 8, 159–172 (2013).
  PubMed PubMed Central Google Scholar
• Sharma, S. V. et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141, 69–80 (2010).
  CAS PubMed PubMed Central Google Scholar
• Yan, H. et al. Drug-tolerant cancer cells show reduced tumor-initiating capacity: depletion of CD44 cells and evidence for epigenetic mechanisms. PLoS ONE 6, e24397 (2011).
  CAS PubMed PubMed Central Google Scholar
• Lee, G.-Y. et al. Stochastic acquisition of a stem cell-like state and drug tolerance in leukemia cells stressed by radiation. Int. J. Hematol. 93, 27–35 (2011).
  PubMed Google Scholar
• Filippakopoulos, P. et al. Selective inhibition of BET bromodomains. Nature 468, 1067–1073 (2010).
  CAS PubMed PubMed Central Google Scholar
• Cheng, Z. et al. Inhibition of BET bromodomain targets genetically diverse glioblastoma. Clin. Cancer Res. 19, 1748–1759 (2013).
  CAS PubMed PubMed Central Google Scholar
• Arrowsmith, C. H., Bountra, C., Fish, P. V., Lee, K. & Schapira, M. Epigenetic protein families: a new frontier for drug discovery. Nature Rev. Drug Discov. 11, 384–400 (2012).
  CAS Google Scholar
• Qian, J., Lu, L., Wu, J. & Ma, H. Development of multiple cell-based assays for the detection of histone H3 Lys27 trimethylation (H3K27me3). Assay Drug Dev. Technol. 11, 449–456 (2013).
  CAS PubMed PubMed Central Google Scholar
• Mulji, A. et al. Configuration of a high-content imaging platform for hit identification and pharmacological assessment of JMJD3 demethylase enzyme inhibitors. J. Biomol. Screen. 17, 108–120 (2012).
  CAS PubMed Google Scholar
• Snuderl, M. et al. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell 20, 810–817 (2011).
  CAS PubMed Google Scholar
• Sottoriva, A. et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc. Natl Acad. Sci. USA 110, 4009–4014 (2013).
  CAS PubMed PubMed Central Google Scholar
• Jiang, P. et al. Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs. J. Transl. Med. 12, 13 (2014).
  PubMed PubMed Central Google Scholar
• Joshi, A. D. et al. Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy. PLoS ONE 7, e44372 (2012).
  CAS PubMed PubMed Central Google Scholar
• Engström, P. G. et al. Digital transcriptome profiling of normal and glioblastoma-derived neural stem cells identifies genes associated with patient survival. Genome Med. 4, 76 (2012).
  PubMed PubMed Central Google Scholar
• Vitucci, M. et al. Cooperativity between MAPK and PI3K signaling activation is required for glioblastoma pathogenesis. Neuro-Oncol. 15, 1317–1329 (2013).
  CAS PubMed PubMed Central Google Scholar
• Kaur, G. et al. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. J. Natl Cancer Inst. 84, 1736–1740 (1992).
  CAS PubMed Google Scholar
• Bax, D. A. et al. Molecular and phenotypic characterisation of paediatric glioma cell lines as models for preclinical drug development. PLoS ONE 4, e5209 (2009).
  PubMed PubMed Central Google Scholar
• Breuleux, M. et al. BAL27862: a unique microtubule destabilizer active against chemorefractory breast cancers. Cancer Res. 69 (Suppl. 24), 2093 (2010).
  Google Scholar
• Joo, K. M. et al. Patient-specific orthotopic glioblastoma xenograft models recapitulate the histopathology and biology of human glioblastomas in situ. Cell Rep. 3, 260–273 (2013).
  CAS PubMed Google Scholar
• Danovi, D., Folarin, A. A., Baranowski, B. & Pollard, S. M. High content screening of defined chemical libraries using normal and glioma-derived neural stem cell lines. Methods Enzymol. 506, 311–329 (2012).
  CAS PubMed Google Scholar
• Mendelsohn, J. Personalizing oncology: perspectives and prospects. J. Clin. Oncol. 31, 1904–1911 (2013).
  CAS PubMed Google Scholar
• Sha, S.-K. et al. Cell cycle phenotype-based optimization of G2-abrogating peptides yields CBP501 with a unique mechanism of action at the G2 checkpoint. Mol. Cancer Ther. 6, 147–153 (2007).
  CAS PubMed Google Scholar
• Hangauer, D. G. Compositions for treating cell proliferation disorders. US Patent 7300931 (2007).
• Dvorakova, K. et al. Induction of oxidative stress and apoptosis in myeloma cells by the aziridine-containing agent imexon. Biochem. Pharmacol. 60, 749–758 (2000).
  CAS PubMed Google Scholar
• Vidal, A. et al. Lurbinectedin (PM01183), a new DNA minor groove binder, inhibits growth of orthotopic primary graft of cisplatin-resistant epithelial ovarian cancer. Clin. Cancer Res. 18, 5399–5411 (2012).
  CAS PubMed Google Scholar
• Hayakawa, F. et al. A novel STAT inhibitor, OPB-31121, has a significant antitumor effect on leukemia with STAT-addictive oncokinases. Blood Cancer J. 3, e166–e169 (2013).
  CAS PubMed PubMed Central Google Scholar
• Guirouilh-Barbat, J., Antony, S. & Pommier, Y. Zalypsis (PM00104) is a potent inducer of γ-H2AX foci and reveals the importance of the C ring of trabectedin for transcription-coupled repair inhibition. Mol. Cancer Ther. 8, 2007–2014 (2009).
  CAS PubMed PubMed Central Google Scholar
• Wiman, K. G. Pharmacological reactivation of mutant p53: from protein structure to the cancer patient. Oncogene 29, 4245–4252 (2010).
  CAS PubMed Google Scholar
• Kirshner, J. R. et al. Elesclomol induces cancer cell apoptosis through oxidative stress. Mol. Cancer Ther. 7, 2319–2327 (2008).
  CAS PubMed Google Scholar
• Sahasrabudhe, S. R. et al. Selective in vitro and in vivo anti-tumor activity of PRLX 93936 in biological models of melanoma and ovarian cancer. J. Clin. Oncol. 26, 14586 (2008).
  Google Scholar
• Funahashi, Y. et al. Sulfonamide derivative, E7820, is a unique angiogenesis inhibitor suppressing an expression of integrin α2 subunit on endothelium. Cancer Res. 62, 6116–6123 (2002).
  CAS PubMed Google Scholar
• Chau, C. H. & Figg, W. D. New tricks from an old drug: a role for quinacrine in anti-cancer therapy? Cell Cycle 8, 4024–4025 (2009).
  CAS PubMed Google Scholar
• Gumireddy, K. et al. ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell 7, 275–286 (2005).
  CAS PubMed Google Scholar
• Hawtin, R. E. et al. Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II. PLoS ONE 5, e10186 (2010).
  PubMed PubMed Central Google Scholar
• Tozer, G. M. et al. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res. 59, 1626–1634 (1999).
  CAS PubMed Google Scholar
• Urdiales, J., Morata, P., De Castro, I. N. & Sánchez-Jiménez, F. Antiproliferative effect of dehydrodidemnin B (DDB), a depsipeptide isolated from Mediterranean tunicates. Cancer Lett. 102, 31–37 (1996).
  CAS PubMed Google Scholar
• Takahashi-Yanaga, F. & Kahn, M. Targeting Wnt signaling: can we safely eradicate cancer stem cells? Clin. Cancer. Res. 16, 3153–3162 (2010).
  CAS PubMed Google Scholar
• Robarge, K. D. et al. GDC-0449 — a potent inhibitor of the hedgehog pathway. Bioorg. Med. Chem. Lett. 19, 5576–5581 (2009).
  CAS PubMed Google Scholar
• Chen, B. et al. Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nature Chem. Biol. 5, 100–107 (2009).
  CAS Google Scholar
• Yamaguchi, T. et al. Identification of JTP-70902, a p15(INK4b)-inductive compound, as a novel MEK1/2 inhibitor. Cancer Sci. 98, 1809–1816 (2007).
  CAS PubMed Google Scholar
• Li, H. et al. Versatile pathway-centric approach based on high-throughput sequencing to anticancer drug discovery. Proc. Natl Acad. Sci. USA 109, 4609–4614 (2012).
  CAS PubMed PubMed Central Google Scholar
• Stoops, S. L. et al. Identification and optimization of small molecules that restore E-cadherin expression and reduce invasion in colorectal carcinoma cells. ACS Chem. Biol. 6, 452–465 (2011).
  CAS PubMed PubMed Central Google Scholar
• Lavelin, I. et al. Discovery of novel proteasome inhibitors using a high-content cell-based screening system. PLoS ONE 4, e8503 (2009).
  PubMed PubMed Central Google Scholar
• Zhang, L. et al. Small molecule regulators of autophagy identified by an image-based high-throughput screen. Proc. Natl Acad. Sci. USA 104, 19023–19028 (2007).
  CAS PubMed PubMed Central Google Scholar
• Roller, D. G. et al. Synthetic lethal screening with small-molecule inhibitors provides a pathway to rational combination therapies for melanoma. Mol. Cancer Ther. 11, 2505–2515 (2012).
  CAS PubMed PubMed Central Google Scholar
• McLaughlin, J. et al. Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen. J. Cancer Res. Clin. Oncol. 136, 99–113 (2010).
  CAS PubMed Google Scholar
• Mayer, T. U. et al. Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science 286, 971–974 (1999).
  CAS PubMed Google Scholar
• Guzi, T. J. et al. Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening. Mol. Cancer Ther. 10, 591–602 (2011).
  CAS PubMed Google Scholar
• Quintavalle, M., Elia, L., Price, J. H., Heynen-Genel, S. & Courtneidge, S. A. A cell-based high-content screening assay reveals activators and inhibitors of cancer cell invasion. Sci. Signal. 4, ra49 (2011).
  CAS PubMed PubMed Central Google Scholar
• Lee, J. et al. A small molecule inhibitor of α4 integrin-dependent cell migration. Bioorg. Med. Chem. 17, 977–980 (2009).
  CAS PubMed Google Scholar
• Yarrow, J. C., Totsukawa, G., Charras, G. T. & Mitchison, T. J. Screening for cell migration inhibitors via automated microscopy reveals a Rho-kinase inhibitor. Chem. Biol. 12, 385–395 (2005).
  CAS PubMed Google Scholar
• Stevens, M. F. & Newlands, E. S. From triazines and triazenes to temozolomide. Eur. J. Cancer 29A, 1045–1047 (1993).
  CAS PubMed Google Scholar
• Gottardis, M. M. et al. Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand. Cancer Res. 56, 5566–5570 (1996).
  CAS PubMed Google Scholar
• Buchdunger, E. et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 56, 100–104 (1996).
  CAS PubMed Google Scholar
• Arteaga, C. L. & Johnson, D. H. Tyrosine kinase inhibitors-ZD1839 (Iressa). Curr. Opin. Oncol. 13, 491–498 (2001).
  CAS PubMed Google Scholar
• Carson, D. A. et al. Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2′-arabino-fluoro-2′-deoxyadenosine. Proc. Natl Acad. Sci. USA 89, 2970–2974 (1992).
  CAS PubMed PubMed Central Google Scholar
• Taylor, E. C. et al. A dideazatetrahydrofolate analogue lacking a chiral center at C-6, _N_-[4-[2-(2-amino-3,4-dihydro-4-oxo-7_H_-pyrrolo[2,3-d]pyrimidin-5- yl)ethyl]benzoyl]-l-glutamic acid, is an inhibitor of thymidylate synthase. J. Med. Chem. 35, 4450–4454 (1992).
  CAS PubMed Google Scholar
• Moyer, J. D. et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. 57, 4838–4848 (1997).
  CAS PubMed Google Scholar
• Giudici, D. et al. 6-methylenandrosta-1,4-diene-3, 17-dione (FCE 24304): a new irreversible aromatase inhibitor. J. Steroid Biochem. 30, 391–394 (1988).
  CAS PubMed Google Scholar
• Kotla, V. et al. Mechanism of action of lenalidomide in hematological malignancies. J. Hematol. Oncol. 2, 36 (2009).
  PubMed PubMed Central Google Scholar
• Gandhi, V. et al. Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical response. J. Clin. Oncol. 16, 3607–3615 (1998).
  CAS PubMed Google Scholar
• Lombardo, L. J. et al. Discovery of _N_-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J. Med. Chem. 47, 6658–6661 (2004).
  CAS PubMed Google Scholar
• Sun, L. et al. Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl- 1_H_-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J. Med. Chem. 46, 1116–1119 (2003).
  CAS PubMed Google Scholar
• Weisberg, E. et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7, 129–141 (2005).
  CAS PubMed Google Scholar
• Wilhelm, S. & Chien, D.-S. BAY 43-9006: preclinical data. Curr. Pharm. Des. 8, 2255–2257 (2002).
  CAS PubMed Google Scholar
• Leoni, L. M. et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin. Cancer Res. 14, 309–317 (2008).
  CAS PubMed Google Scholar
• Podar, K. et al. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proc. Natl Acad. Sci. USA 103, 19478–19483 (2006).
  CAS PubMed PubMed Central Google Scholar
• Xia, W. et al. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 21, 6255–6263 (2002).
  CAS PubMed Google Scholar
• Potter, G. A., Barrie, S. E., Jarman, M. & Rowlands, M. G. Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer. J. Med. Chem. 38, 2463–2471 (1995).
  CAS PubMed Google Scholar
• Cui, J. J. et al. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J. Med. Chem. 54, 6342–6363 (2011).
  CAS PubMed Google Scholar
• Quintás-Cardama, A. et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 115, 3109–3117 (2010).
  PubMed PubMed Central Google Scholar
• Hennequin, L. F. et al. Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. J. Med. Chem. 45, 1300–1312 (2002).
  CAS PubMed Google Scholar
• Bollag, G. et al. Vemurafenib: the first drug approved for BRAF-mutant cancer. Nature Rev. Drug Discov. 11, 873–886 (2012).
  CAS Google Scholar
• Inai, T. et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am. J. Pathol. 165, 35–52 (2004).
  CAS PubMed PubMed Central Google Scholar
• Puttini, M. et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res. 66, 11314–11322 (2006).
  CAS PubMed Google Scholar
• Zhang, Y., Guessous, F., Kofman, A., Schiff, D. & Abounader, R. XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC. IDrugs 13, 112–121 (2010).
  PubMed PubMed Central Google Scholar
• Demo, S. D. et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res. 67, 6383–6391 (2007).
  CAS PubMed Google Scholar
• Huang, W.-S. et al. Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-_N_-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant. J. Med. Chem. 53, 4701–4719 (2010).
  CAS PubMed Google Scholar
• Li, D. et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27, 4702–4711 (2008).
  CAS PubMed PubMed Central Google Scholar
• Medina, T., Amaria, M. N. & Jimeno, A. Dabrafenib in the treatment of advanced melanoma. Drugs Today 49, 377–385 (2013).
  CAS Google Scholar
• Honigberg, L. A. et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc. Natl Acad. Sci. USA 107, 13075–13080 (2010).
  CAS PubMed PubMed Central Google Scholar